ArticleCancer immunology, immunotherapy : CII2022

Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit.

Emily Nickles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.